{"entity":{"id":"opb-201","kind":"drug","name":"OPB-201","aka":[],"tldr":"OPB-201 is an experimental autologous TCR T-cell therapy from Outpace Bio, in phase 1 trials for recurrent endometrial cancer, platinum-resistant ovarian cancer and other solid tumours.","summary":"OPB-201 is an autologous TCR T-cell therapy from Outpace Bio. Autologous T cells carrying an optimised T-cell receptor for a PRAME-derived peptide plus a designed protein that boosts their potency. Its furthest stage is phase 1, for recurrent endometrial cancer, platinum-resistant ovarian cancer and other solid tumours. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Outpace Bio: outpacebio.com","url":"https://outpacebio.com/our-science"},{"label":"Outpace Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07664735"},{"label":"ClinicalTrials.gov: trials of OPB-201","url":"https://clinicaltrials.gov/search?intr=OPB-201"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","platinum-resistant-ovarian-cancer","metastatic-cancer"],"sections":[],"technologies":[],"targets":["prame"],"drugs":[],"companies":["outpace-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07664735"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"OPB-201","modality":"Autologous TCR T-cell therapy","mechanism":"Autologous T cells carrying an optimised T-cell receptor for a PRAME-derived peptide plus a designed protein that boosts their potency.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/opb-201/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"company":[{"id":"outpace-bio","kind":"company","name":"Outpace Bio","route":"/companies/outpace-bio/"}],"trial":[{"id":"nct07664735","kind":"trial","name":"A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","route":"/trials/nct07664735/"}]}}